Analyst consensus rating
ACADIA Pharmaceuticals Analyst Rating: Buy
ACAD is rated Buy by 20 analysts with a $34.00 target. As of 2026-08-29.
Direct answer
ACADIA Pharmaceuticals's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.00.
Forecast evidence checked August 29, 2026.
Get free ACADIA Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $29.11
- Average price target
- $34.00
- High price target
- $49.00
- Low price target
- $17.00
- Low target gap
- -41.6%
- Target upside
- +16.8%
- High target gap
- +68.3%
- Target range width
- 109.9%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $34.00.
How far are ACADIA Pharmaceuticals's low and high targets from the recorded price?
The low target implies -41.6%, while the high target implies +68.3%.
How many analysts are included in ACADIA Pharmaceuticals's consensus?
The verified consensus includes 20 analysts.
How is ACADIA Pharmaceuticals's target upside or downside calculated?
The average target of $34.00 is divided by the recorded price of $29.11, then one is subtracted to produce +16.8%. This does not guarantee a future return.
When was ACADIA Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.